The FDA issued a Complete Response Letter on June 2, 2026, for Cingulate Inc.'s New Drug Application for CTx-1301, a once-daily ADHD medication designed to eliminate afternoon booster doses. The letter requests additional Chemistry, Manufacturing and Controls (CMC) information and raises no concerns about the drug's safety or efficacy based on clinical trial results.

The PDUFA target action date was May 31, 2026. Cingulate plans a prompt resubmission.

What Changed

A Complete Response Letter doesn't reject a drug application. It means the FDA needs more information before approval. In this case, the agency's questions focus entirely on manufacturing processes and quality controls, not on how well the drug works or whether it's safe for patients.

CEO Shane J. Schaffer stated in the company's announcement: "We are encouraged that the FDA's response was limited to specific information requests related to CMC and did not currently identify any issues related to the clinical safety or efficacy of CTx-1301."

Cingulate has approximately $30 million in cash reserves, which the company believes provides sufficient funding to address the FDA's requests and continue pre-commercial activities into 2027.

What CTx-1301 Is

CTx-1301 uses dexmethylphenidate HCl, the same active ingredient in other ADHD medications, delivered through Cingulate's proprietary Precision Timed Release (PTR) technology. The once-daily tablet contains three cores that release medication at precisely timed intervals throughout the day.

Phase 3 clinical trials demonstrated statistically significant efficacy in children ages 6 and older and adults. The trials also showed a favorable safety profile, meaning the side effects observed were manageable and consistent with other stimulant medications in this class.

The design targets a common treatment gap: over 60% of ADHD patients currently use afternoon booster doses to extend medication coverage through homework time, after-school activities, and evening routines. A once-daily medication that covers the full active day would eliminate the need for school nurses to administer midday doses and reduce the burden on families managing multiple medications.

Why This Matters for Special Needs Families

Many children with autism, learning disabilities, or other developmental conditions also have ADHD. Managing medication across school, therapy, and home settings adds logistical complexity. Sensory accommodations for ADHD often run alongside behavioral and pharmacological interventions, and a once-daily option simplifies one piece of that coordination.

This delay doesn't change current treatment plans. It's a documentation review, not a clinical failure. Families managing ADHD medication concerns should continue their existing regimens and discuss any questions with their providers.

The U.S. ADHD market includes over 20 million diagnosed individuals: 12 million adults and more than 8 million children under 17. Despite widespread diagnosis, only 53.6% of affected children actively manage symptoms with medication as of 2022, according to CDC data. Barriers include side effect concerns, dosing inconvenience, and gaps in coverage during critical parts of the day.

What Families Can Do Now

• Continue your child's current ADHD treatment without changes. A CRL for a drug not yet on the market doesn't affect medications already prescribed.
• If your child needs afternoon booster doses at school, review your Section 504 or IEP to ensure medication administration is documented and the school has current prescriptions on file.
• Ask your prescriber about long-acting ADHD medications currently available if you're seeking fewer daily doses.
• Monitor Cingulate's investor relations page or ask your provider about CTx-1301 resubmission news if this medication profile interests your family.

Timeline

• October 2025: FDA accepted the New Drug Application for CTx-1301
• May 31, 2026: PDUFA target action date
• June 2, 2026: FDA issued Complete Response Letter requesting CMC information
• 2027: Cingulate expects to continue pre-commercial activities pending resubmission and approval

A CRL extends the approval timeline but doesn't close the door. The FDA's focus on manufacturing details rather than clinical data suggests the drug's performance in trials met the agency's standards. The remaining work addresses how the medication is produced and quality-controlled, not whether it works.

Families waiting for new ADHD treatment options can expect resubmission announcements in coming months. In the meantime, existing long-acting formulations remain the standard of care.

Sources:

• Cingulate Inc. SEC 8-K Filing (June 2, 2026)
• Yahoo Finance: Cingulate Receives Complete Response Letter